Allogeneic hematopoietic stem cell transplantation secondary second of Cancer.docVIP

 PAGE \* MERGEFORMAT 15 Allogeneic hematopoietic stem cell transplantation secondary second of Cancer Keywords: allogeneic hematopoietic stem cell transplantation immunosuppression second tumor In recent years, pairs of leukemia after allogeneic hematopoietic stem cell transplantation (Allo  HSCT) study, suggesting that Allo  HSCT is an effective method for the treatment of leukemia. The second post-transplant secondary tumors Allo  HSCT after a long-term complications, according to the order of occurrence time is usually divided into post-transplant lymphoproliferative disease (Posttransplant lymphoproliferative disorders, PTLD), myelodysplastic syndrome (MDS ) / leukemia and solid tumors. Reduce the incidence of second tumors in patients with long-term survival after transplantation, affecting the long-term efficacy of the graft. In this paper, the second secondary tumors after transplantation-related issues are reviewed in order to raise awareness of awareness of such diseases. A post-transplant lymphoproliferative disease 1.1 PTLD pathogenesis of Wanger et al [1] through quantitative PCR monitoring in patients with HSCT transplantation in 85 patients specimens of 1,300 copies of EBV  DNA level of EBV  DNA was found at a lower level were not occur in patients with PTLD, 25 patients with elevated levels of EBV, including eight cases of the development of for PTLD, the incidence of PTLD and EBV prompted to close. Because there are EBV-specific B-lymphocyte surface receptor, B lymphocytes as EBV target cells can be transformed by EBV infection has been transformed over the cells in a latent state, when the body’s immune status is changed, EBV can be activated , copy, and even the body of the cells were transformed state of infinite reproduction, eventually leading to the occurrence of PTLD. One latent membrane protein 1 (LMP  1) play a key role, it can induce the expression of bcl  2 and prevent apoptosis of EBV i